share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  06/12 17:27
Moomoo AI 已提取核心信息
On June 11, 2024, 60 Degrees Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug tafenoquine for the treatment of acute babesiosis. This designation provides the company with benefits such as market exclusivity, tax credits, and exemption from certain FDA fees. The company has also partnered with Tufts Medical Center to conduct the first clinical trial evaluating tafenoquine's efficacy and safety in treating human babesiosis. Babesiosis is a disease transmitted by ticks, which can be severe in certain populations. The trial is set to begin recruitment on June 13, 2024, and will involve at least 24 patients. Tafenoquine is already approved for malaria prophylaxis under the name ARAKODA®. The company, which specializes in developing treatments for infectious diseases, is headquartered in Washington D.C. and has a subsidiary in Australia.
On June 11, 2024, 60 Degrees Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug tafenoquine for the treatment of acute babesiosis. This designation provides the company with benefits such as market exclusivity, tax credits, and exemption from certain FDA fees. The company has also partnered with Tufts Medical Center to conduct the first clinical trial evaluating tafenoquine's efficacy and safety in treating human babesiosis. Babesiosis is a disease transmitted by ticks, which can be severe in certain populations. The trial is set to begin recruitment on June 13, 2024, and will involve at least 24 patients. Tafenoquine is already approved for malaria prophylaxis under the name ARAKODA®. The company, which specializes in developing treatments for infectious diseases, is headquartered in Washington D.C. and has a subsidiary in Australia.
2024年6月11日，60 Degrees Pharmaceuticals公司宣布美国食品药品监督管理局（FDA）授予其研究药物替硝唑酮孤儿药物认定，用于治疗急性巴贝氏菌病。该认定为公司提供市场排他授权、税收抵免和从某些FDA费用中免除等福利。该公司还与图夫茨医学中心合作开展第一项临床试验，评估替硝唑酮治疗人类巴贝氏菌病的疗效和安全性。巴贝氏菌病是一种由蜱传播的疾病，在某些人群中可能很严重。该试验计划于2024年6月13日开始招募，将涉及至少24名患者。替硝唑酮已获得阿拉科达®的疟疾预防批准。该公司专门开发治疗传染病的药物，总部位于华盛顿特区，其在澳洲设有子公司。
2024年6月11日，60 Degrees Pharmaceuticals公司宣布美国食品药品监督管理局（FDA）授予其研究药物替硝唑酮孤儿药物认定，用于治疗急性巴贝氏菌病。该认定为公司提供市场排他授权、税收抵免和从某些FDA费用中免除等福利。该公司还与图夫茨医学中心合作开展第一项临床试验，评估替硝唑酮治疗人类巴贝氏菌病的疗效和安全性。巴贝氏菌病是一种由蜱传播的疾病，在某些人群中可能很严重。该试验计划于2024年6月13日开始招募，将涉及至少24名患者。替硝唑酮已获得阿拉科达®的疟疾预防批准。该公司专门开发治疗传染病的药物，总部位于华盛顿特区，其在澳洲设有子公司。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息